Rasagiline for the treatment of advanced Parkinson’s disease
Rasagiline improves the bioavailability of dopamine and is often used in combination with levodopa, especially in patients with advanced Parkinson's disease. The analysis showed that patients who received rasagiline 1 mg/day as monotherapy or as part of a combination levodopa regimen had greater improvements in total UPDRS scores compared with patients who received placebo. Although rasagiline's efficacy in advanced Parkinson's disease is generally accepted as early monotherapy and as an adjunct to levodopa therapy, its efficacy in combination with other drugs for the treatment of Parkinson's disease symptoms is less clear.

Dopamine receptor agonists(DAs) have been used to treat Parkinson's disease for nearly 40 years. Although DAs can be successfully used as monotherapy in the early stages of the disease, their efficacy in long-term treatment is poor, and approximately 50% of patients have levodopa added after 5 years. Because levodopa is associated with the development of motor complications, which depend on the timing of levodopa initiation and duration of exposure, the study results showed that the rasagiline/DA combination treatment group showed a significant improvement in the total UPDRS score from baseline to week 18.
The original drug of rasagiline has been launched in China and has entered the category of Class B medical insurance. The common name is rasagiline mesylate tablets, and the specifications areThe price of each box of 1mg*14 tablets may be around RMB 600. The price of the Turkish version of rasagiline's original drug, 1mg*30 tablets, per box sold overseas may be around RMB 310 (the price may fluctuate due to exchange rates). There are also generic drugs produced in other countries. The price of a box of 1mg*100 tablets produced by an Indian pharmaceutical factory may be around RMB 240 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs. For specific prices and drug information, please consult Yaode Medical Consultants.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)